Combination therapy of ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis: The end of the steroid era in autoimmune liver diseases?

American Journal of Gastroenterology

Volumn 110, Issue 7, 2015, Pages 1086-

  Licinio, Raffaele ^a   Facciorusso, Antonio ^b   Castellaneta, Nicola Maurizio ^a   Di Leo, Alfredo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; BUDESONIDE; LOW DENSITY LIPOPROTEIN; STEROID; URSODEOXYCHOLIC ACID;

AUTOIMMUNE LIVER DISEASE; BONE METABOLISM; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; KIDNEY DYSFUNCTION; LETTER; LIPID METABOLISM; POST TREATMENT SURVIVAL; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; DYSLIPIDEMIAS; FEMALE; KIDNEY FAILURE; LIVER CIRRHOSIS, BILIARY; MALE; MYALGIA;

BEZAFIBRATE; DYSLIPIDEMIAS; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MYALGIA; RENAL INSUFFICIENCY; URSODEOXYCHOLIC ACID;

EID: 84936803132     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.163     Document Type: Letter

References (6)

1. Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-Term combination therapy using ursodeoxycholic acid and bezafi brate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015; 110: 423-31.
2. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303.
3. Leuschner M, Maier K-P, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective douple-blind trial. Gastroenterology 1999; 117: 918-25.
4. Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006; 55: 1795-800.
5. Lichtenstein GR, Bengtsson B, Hapten-White L et al. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther 2009; 29: 643-53.
6. Rautiainen H, Färkkilä M, Neuvonen M, et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther 2006; 24: 1545-52.